CTRI/2018/12/016816招募中3 期
HYPOfractionated Radiation Therapy comparing a standard radiotherapy schedule (over three weeks) with a novel one week schedule in Adjuvant breast cancer: An open label randomised controlled study - HYPORT Adjuvant
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically or cytologically confirmed invasive breast cancers
- •2. ECOG performance status : 0 - 3
- •3. Underwent curative intent surgery for the breast cancer with complete microscopic resection either in the form of a mastectomy or breast conservation surgery
- •4. Adequate axillary clearance or a validated sentinel node biopsy procedure. For the purpose of this study, adequacy of the axillary clearance will be determined by a multidisciplinary tumor board and rationale for the decision documented in the case records. As a general guideline, at least 10 axillary lymph nodes need to be sampled for an axillary nodal dissection to be considered as adequate.
- •5. Absence of distant metastases. Patients who have high risk breast cancer as defined by a Nottingham Prognostic Index (NPI) of > 5.4 will be considered for metastatic workup in the form of a 18 FDG PET CT. Alternatively, a CT scan of the thorax and whole abdomen, and a bone scan is also allowed. Metastatic workup will also be recommended in patients with AJCC 8 T3/T4 tumors at presentation, 4 or more nodes positive after surgery (pN2 or above). Patients with low or intermediate NPI will be considered for metastatic workup on a case by case basis. Metastatic workup will also be recommended for all patients undergoing neoadjuvant chemotherapy for locally advanced breast cancers.
- •6. Clear margins of resection for the breast primary as defined by absence tumor on ink in the specimen if a breast conservation has been performed or excision upto the deep fascia of the pectoralis major or skin.
- •7. Adjuvant radiotherapy is indicated. The following patients will be considered as candidates to receive adjuvant radiotherapy:
- •A. All patients after breast conservation surgery or after neoadjuvant chemotherapy
- •B. Patients after mastectomy if any of the below:
- •i. T3 - T4 tumors
- •ii. > 3 axillary lymph nodes
- •iii. T0-T2 tumor with 0 - 3 axillary lymph nodes with a Cambridge Score of 3 or more.
- •The SCF will be included in patients with axillary nodal involvement in pathology or in those patients who have undergone neoadjuvant chemotherapy. The internal mammary nodes will be included based on the institutional policy.
排除标准
- •1. Patients with pure ductal carcinomas in situ (in patients undergoing upfront surgery).
- •2. Patients with non-epithelial malignant conditions of the breast viz. Sarcomas, lymphomas, phyllodes tumors
- •3. Patients with metaplastic breast cancers
- •4. Presence of pathologically proven residual supraclavicular nodal metastases or residual internal mammary lymphadenopathy at time of radiotherapy.
- •5. Prior radiotherapy to the ipsilateral breast/chest wall or the mediastinum. Patients with synchronous / metachronous contralateral breast malignancies will be eligible for inclusion. Patients requiring bilateral breast radiotherapy are also eligible for inclusion.
- •Concurrent illness, including severe infection that may jeopardize the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety
- •7. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.
- •8. Patients planned for concurrent chemotherapy during radiation therapy. Concurrent hormonal therapy or targeted therapy using anti-HER2 agents is allowed.
研究者
相似试验
招募中
不适用
Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving SurgeryBreast CancerNCT04025164Fudan University4,052
招募中
不适用
One Week Versus Three Week in Adjuvant Radiotherapy in Breast CancerBreast Cancer FemaleNCT03788213Tata Medical Center2,100
已完成
1 期
Hypofractionated radiotherapy for low and intermediate-risk prostate cancer using robot-tracking stereotactic radiotherapy -phase I/II clinical trialprostate cancerJPRN-UMIN000014328Osaka University Graduate School of Medicine75
招募中
2 期
Two-fraction Ultra-hypofractionated Radiotherapy with Focal Boost for low- and intermediate risk, localized prostate cancer (TURBO):phase II, randomized controlled clinical trialprostate adenocarcinoma100276561001818810036958prostate cancerNL-OMON56580niversitair Medisch Centrum Utrecht160
进行中（未招募）
不适用
Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancerKCT0005443ational Cancer Center35